|
Sex, male/female
|
40/26
|
34/22
|
1.0
|
|
Median age, years (range)
|
59 (15–87)
|
54.5 (10–93)
|
0.128
|
|
Median WBC, ×109/L (range)
|
14.5 (0.8–528)
|
26.75 (0.3–197)
|
0.313
|
|
Median hemoglobin, g/L (range)
|
74.5 (34–138)
|
78.5 (49–135)
|
0.134
|
|
Median platelets, ×109/L (range)
|
41 (3–264)
|
39.5 (5–415)
|
0.921
|
|
BM blasts, % (range)
|
46.25 (5.5–99)
|
42 (1–94.5)
|
0.197
|
|
CR (−/+)
|
33/30
|
29/24
|
0.853
|
|
FAB classification
| | |
0.428
|
|
M0
|
1 (1.5%)
|
0 (0%)
| |
|
M1
|
6 (9.1%)
|
2 (3.6%)
| |
|
M2
|
29 (43.9%)
|
19 (33.9%)
| |
|
M3
|
8 (12.2%)
|
15 (26.8%)
| |
|
M4
|
13 (19.7%)
|
12 (21.4%)
| |
|
M5
|
8 (12.1%)
|
7 (12.5%)
| |
|
M6
|
1 (1.5%)
|
1 (1.8%)
| |
|
Karyotype classification
| | |
0.666
|
|
Favorable
|
18 (27.3%)
|
19 (33.9%)
| |
|
Intermediate
|
37 (56.1%)
|
28 (50%)
| |
|
Adverse
|
8 (12.1%)
|
7 (12.5%)
| |
|
No data
|
3 (4.5%)
|
2 (3.6%)
| |
|
Karyotype
| | |
0.423
|
|
normal
|
27 (40.9%)
|
20 (35.7%)
| |
|
t(8;21)
|
8 (12.1%)
|
4 (7.1%)
| |
|
t(15;17)
|
9 (13.6%)
|
15 (26.8%)
| |
|
11q23
|
0 (0)
|
0 (0)
| |
|
complex
|
8 (12.1%)
|
5 (8.9%)
| |
|
others
|
11 (15.2%)
|
10 (30.4%)
| |
|
No data
|
3 (4.5%)
|
2 (3.6%)
| |
|
Gene mutation
|
|
CEBPA (+/−)
|
10/51
|
3/41
|
0.229
|
|
NPM1 (+/−)
|
4/57
|
3/41
|
1.00
|
|
FLT3-ITD (+/−)
|
7/54
|
5/39
|
1.00
|
|
KIT (+/−)
|
2/59
|
2/42
|
1.00
|
|
N/K-RAS (+/−)
|
8/53
|
2/42
|
0.187
|
|
IDH1/2 (+/−)
|
2/59
|
2/42
|
1.00
|
|
DNMT3A (+/−)
|
4/57
|
5/39
|
0.487
|
|
U2AF1 (+/−)
|
2/59
|
1/43
|
1.00
|
